Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

References

• Johnson WD Kroon JJ Greenway FL Bouchard C Ryan D Katzmarzyk PT Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001–2006 Arch Pediatr Adolesc Med 2009 163 371 377 19349567
   PubMed Web of Science ®Google Scholar
• Ryan JG Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus Gend Med 2009 6 Suppl 1 86 108 19318221
   PubMedGoogle Scholar
• ADA 2008 Standards of medical care in diabetes – 2008 Diabetes Care 2008 31 Suppl 1 S12 S54 18165335
   PubMed Web of Science ®Google Scholar
• Nathan DM Finding new treatments for diabetes–how many, how fast... how good? N Engl J Med 2007 356 437 440 17267901
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffner SM Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Turner RC Cull CA Frighi V Holman RR Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 1999 281 2005 2012 10359389
   PubMed Web of Science ®Google Scholar
• Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Colao A Di Sarno A Guerra E De Leo M Mentone A Lombardi G Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women Nat Clin Pract Endocrinol Metab 2006 2 200 210 16932285
   PubMedGoogle Scholar
• Cincotta AH Meier AH Cincotta MJr Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes Expert Opin Investig Drugs 1999 8 1683 1707
   PubMedGoogle Scholar
• Scranton R Cincotta A Gaziano JM The effect of timed Cycloset (a quick-release formulation of bromocriptine mesylate) on cardiovascular events in patients with type 2 diabetes [abstract] Diabetes 2008 57 A95
   Web of Science ®Google Scholar
• Scranton RE Gaziano JM Rutty D Ezrokhi M Cincotta A A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo BMC Endocr Disord 2007 7 3 17592632
   PubMedGoogle Scholar
• Kvernmo T Hartter S Burger E A review of the receptor-binding and pharmacokinetic properties of dopamine agonists Clin Ther 2006 28 1065 1078 16982285
   PubMed Web of Science ®Google Scholar
• Sandoval D Cota D Seeley RJ The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation Annu Rev Physiol 2008 70 513 535 17988209
   PubMed Web of Science ®Google Scholar
• Tschoner A Engl J Laimer M Metabolic side effects of antipsychotic medication Int J Clin Pract 2007 61 1356 1370 17627711
   PubMed Web of Science ®Google Scholar
• Cincotta AH MacEachern TA Meier AH Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters Am J Physiol 1993 264 E285 E293 8447396
   PubMed Web of Science ®Google Scholar
• Cincotta AH Meier AH Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment Life Sci 1989 45 2247 2254 2601578
   PubMed Web of Science ®Google Scholar
• Cincotta AH Meier AH Southern LL Bromocriptine alters hormone rhythms and lipid metabolism in swine Ann Nutr Metab 1989 33 305 314 2694921
   PubMed Web of Science ®Google Scholar
• Southern LL Cincotta AH Meier AH Bidner TD Watkins KL Bromocriptine-induced reduction of body fat in pigs J Anim Sci 1990 68 931 936 2332392
   PubMed Web of Science ®Google Scholar
• Cincotta AH Schiller BC Meier AH Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus Metabolism 1991 40 639 644 1865827
   PubMed Web of Science ®Google Scholar
• Cincotta AH Meier AH Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 1996 19 667 670 8725871
   PubMed Web of Science ®Google Scholar
• Pijl H Ohashi S Matsuda M Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23 1154 1161 10937514
   PubMed Web of Science ®Google Scholar
• Aminorroaya A Janghorbani M Ramezani M Haghighi S Amini M Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004 62 55 59 15205563
   PubMed Web of Science ®Google Scholar
• Kamath V Jones CN Yip JC Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women Diabetes Care 1997 20 1697 1701 9353611
   PubMed Web of Science ®Google Scholar
• Meier AH Cincotta AH Lovell WC Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics Experientia 1992 48 248 253 1547854
   PubMedGoogle Scholar
• Wasada T Kawahara R Iwamoto Y Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients Diabetes Care 2000 23 1039 1040 10895875
   PubMed Web of Science ®Google Scholar
• Tan EK Jankovic J Choosing dopamine agonists in Parkinson’s disease Clin Neuropharmacol 2001 24 247 253 11586109
   PubMed Web of Science ®Google Scholar
• Jahnichen S Horowski R Pertz HH Agonism at 5-HT2B receptors is not a class effect of the ergolines Eur J Pharmacol 2005 513 225 228 15862804
   PubMed Web of Science ®Google Scholar
• http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=1020 Accessed Dec 10, 2009
   Google Scholar
• Scranton REEM Gaziano JM Cincotta A Cycloset (bromocriptine mesylate accelerated absorbing) therapy improves glycemic control in type 2 diabetes (T2D) subjects failing thiazolidinedione (TZD) therapy [abstract] American Diabetes Association 69th Annual Meeting June 8, 2009 Abstract 481-P
   Google Scholar
• van Hilten JJ Ramaker CC Stowe R Ives NJ Bromocriptine versus levodopa in early Parkinson’s disease Cochrane Database Syst Rev 2007 CD002258 17943771
   PubMed Web of Science ®Google Scholar
• Weil C The safety of bromocriptine in long-term use: a review of the literature Curr Med Res Opin 1986 10 25 51 3516579
   PubMed Web of Science ®Google Scholar
• Wiggins J Skinner C Bromocriptine induced pleuropulmonary fibrosis Thorax 1986 41 328 330 3738853
   PubMed Web of Science ®Google Scholar
• Horvath J Fross RD Kleiner-Fisman G Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists Mov Disord 2004 19 656 662 15197703
   PubMed Web of Science ®Google Scholar
• Zanettini R Antonini A Gatto G Gentile R Tesei S Pezzoli G Valvular heart disease and the use of dopamine agonists for Parkinson’s disease N Engl J Med 2007 356 39 46 17202454
   PubMed Web of Science ®Google Scholar
• Serratrice J Disdier P Habib G Viallet F Weiller PJ Fibrotic valvular heart disease subsequent to bromocriptine treatment Cardiol Rev 2002 10 334 336 12390688
   PubMedGoogle Scholar
• Daly JM Hartz AJ Xu Y An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes J Am Board Fam Med 2009 22 280 290 19429734
   PubMed Web of Science ®Google Scholar
• Katzenschlager R Head J Schrag A Ben-Shlomo Y Evans A Lees AJ Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD Neurology 2008 71 474 480 18579806
   PubMed Web of Science ®Google Scholar
• Sahay BK Sahay RK Hypertension in diabetes J Indian Med Assoc 2003 101 12 14 15 44 12841500
   PubMedGoogle Scholar
• Clausius N Born C Grunze H The relevance of dopamine agonists in the treatment of depression Neuropsychiatr 2009 23 15 25 19272288
   PubMed Web of Science ®Google Scholar